FLGT — Fulgent Genetics Cashflow Statement
0.000.00%
Last trade - 00:00
- $621.34m
- $199.85m
- $289.21m
- 84
- 35
- 72
- 68
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.411 | 214 | 506 | 142 | -175 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 4.76 | 16.6 | 32.2 | 85.2 | 162 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.915 | -91.5 | -2.68 | 2 | 2.84 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Cash from Operating Activities | 5.52 | 141 | 539 | 254 | 27 |
Capital Expenditures | -1.18 | -35.1 | -23.8 | -18.8 | -22.2 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -27.9 | -291 | -523 | -243 | 61.1 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -29 | -326 | -547 | -261 | 38.9 |
Financing Cash Flow Items | — | — | 0.01 | 0 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 28.8 | 261 | 85.4 | -77.1 | -47.8 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5.23 | 75.5 | 77.5 | -85.4 | 18 |